Screener
ADMA Biologics ADMA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Taxes paid on vested restricted stock units | (8,986) | (8,419) |
| Net proceeds from the exercise of stock options | 623 | 2,165 |
| Payment of end of term fee | - | (375) |
| Acquisition of treasury stock | (155,245) | - |
| Net cash used in financing activities | (39,546) | (7,079) |
| Net increase (decrease) in cash and cash equivalents | 48,390 | (12,862) |
| Cash and cash equivalents - beginning of period | 87,630 | 103,147 |
| Cash and cash equivalents - end of period | $$136,020 | 90,285 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's financing cash flow?
- ADMA Biologics (ADMA) reported financing cash flow of -$29.42M in Q2 2026.
- What is the long-term trend for ADMA Biologics's financing cash flow?
- Over 3 years (2021 to 2025), ADMA Biologics's financing cash flow has grown at a -28.6% compound annual growth rate (CAGR), from $121.05M to -$44.07M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about ADMA Biologics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude